A remarkable clinical response to immune checkpoint inhibitors of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity

•We first to report a 64-year-old woman of Mucoepidermoid carcinoma of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity treated with Capecitabine plus sintilimab and response evaluation was partial response (PR).•For MSI-H high grade Muc...

Full description

Saved in:
Bibliographic Details
Published inOral oncology Vol. 136; p. 106190
Main Authors Pan, Yanling, Li, Yijie, Yuan, Feng, Lin, Zhiren, Chai, Huizi, Xiao, Mingzhe, Chen, Dongsheng
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.01.2023
Subjects
Abdominal Cavity - pathology
Carcinoma, Mucoepidermoid - pathology
Humans
Immune Checkpoint Inhibitors
Parotid Gland - pathology
Parotid Neoplasms - pathology
Online AccessGet full text

Cover

Abstract •We first to report a 64-year-old woman of Mucoepidermoid carcinoma of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity treated with Capecitabine plus sintilimab and response evaluation was partial response (PR).•For MSI-H high grade Mucoepidermoid carcinoma of the parotid gland, anti-PD-1 immunotherapy could be considered to further improve therapeutic qualities and prognosis.•Our case showed an encouraging efficacy of Capecitabine plus sintilimab combination therapy. This promising avenue deserves further study to apply this combination regimen to clinical practice.
AbstractList •We first to report a 64-year-old woman of Mucoepidermoid carcinoma of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity treated with Capecitabine plus sintilimab and response evaluation was partial response (PR).•For MSI-H high grade Mucoepidermoid carcinoma of the parotid gland, anti-PD-1 immunotherapy could be considered to further improve therapeutic qualities and prognosis.•Our case showed an encouraging efficacy of Capecitabine plus sintilimab combination therapy. This promising avenue deserves further study to apply this combination regimen to clinical practice.
ArticleNumber 106190
Author Lin, Zhiren
Chen, Dongsheng
Li, Yijie
Xiao, Mingzhe
Yuan, Feng
Chai, Huizi
Pan, Yanling
Author_xml – sequence: 1
  givenname: Yanling
  surname: Pan
  fullname: Pan, Yanling
  email: 1037444804@qq.com
  organization: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570100, China
– sequence: 2
  givenname: Yijie
  surname: Li
  fullname: Li, Yijie
  email: 371148412@qq.com
  organization: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570100, China
– sequence: 3
  givenname: Feng
  surname: Yuan
  fullname: Yuan, Feng
  email: yuanfeng@csco.ac.cn
  organization: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570100, China
– sequence: 4
  givenname: Zhiren
  surname: Lin
  fullname: Lin, Zhiren
  email: abc697000@163.com
  organization: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570100, China
– sequence: 5
  givenname: Huizi
  surname: Chai
  fullname: Chai, Huizi
  email: huizi.chai@simceredx.com
  organization: The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing 210002, China
– sequence: 6
  givenname: Mingzhe
  surname: Xiao
  fullname: Xiao, Mingzhe
  email: mingzhe.xiao@simceredx.com
  organization: The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing 210002, China
– sequence: 7
  givenname: Dongsheng
  surname: Chen
  fullname: Chen, Dongsheng
  email: dongsheng.chen@simceredx.com
  organization: The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing 210002, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36463699$$D View this record in MEDLINE/PubMed
BookMark eNqNkd1uFSEUhYmpsT_6CoZ45c0cYf7xrmnVNmnjhb0nDOw5s08HGIGpOY_lG8rxVOOlCQmE9e29NqxzcuK8A0LecbbhjLcfdhsf1Oyd9rPf7jclK8sstFywF-SM950oWCOqk3yu2r7oq645Jecx7hhjDW_YK3JatXVbtUKckZ-XNIBV4VENM1A9o0Ot5nwXF-8i0OQpWru6rE2gHxePLlF0Ew6YfIjUj_T-221xQyfcTnQblAF6v2oPCxoI1qOhWgWNzlt1gNMEdFHBpyxsZ-UM_YFponadEy55AgtJxbwgZpfftBqMt-jyUFo9Ydq_Ji9HNUd487xfkIfPnx6uboq7r19ury7vCl31LBWlaMaBa9b1bVU3ooaOcaGEblRVq64ejak1AC-FGLpRDD3Xghsjqm4cO17X1QV5f2y7BP99hZikxahhzjODX6Msu7pjrGxFk9GPR1QHH2OAUS4B85_uJWfykJjcyX8Tk4fE5DGxXPz22WcdLJi_pX8iysD1EYD82CeEIKNGcBoMBtBJGo__4_MLdXe0YA
CitedBy_id crossref_primary_10_1007_s40278_023_36712_6
Cites_doi 10.1097/PAS.0000000000001252
10.5858/arpa.2016-0259-SA
10.1016/j.oraloncology.2018.04.001
10.1200/JCO.19.02105
10.1038/ng1083
10.1002/hed.26735
10.1016/S1470-2045(10)70245-X
10.1177/107327480901600103
10.1200/JCO.19.02107
ContentType Journal Article
Copyright 2022 Elsevier Ltd
Copyright_xml – notice: 2022 Elsevier Ltd
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1016/j.oraloncology.2022.106190
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Dentistry
EISSN 1879-0593
EndPage 106190
ExternalDocumentID 10_1016_j_oraloncology_2022_106190
36463699
S1368837522004791
Genre Letter
Correspondence
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
29N
3O-
4.4
457
4CK
4G.
53G
5RE
5VS
7-5
71M
8P~
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAWTL
AAXUO
ABBQC
ABFNM
ABJNI
ABLJU
ABLVK
ABMAC
ABMZM
ABOCM
ABXDB
ABYKQ
ACDAQ
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
AEBSH
AEKER
AENEX
AEVXI
AFCTW
AFKWA
AFRHN
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHPSJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
AXJTR
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HVGLF
HZ~
IHE
J1W
K-O
KOM
L7B
LCYCR
M41
MO0
N9A
O-L
O9-
OAUVE
OC~
OO-
OZT
P-8
P-9
P2P
PC.
Q38
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSZ
T5K
X7M
XPP
Z5R
ZA5
ZGI
~G-
AAXKI
AFJKZ
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c380t-295fb1c078634594e7019a9c5a34a74fdd4cee1299b7f9b81c91dd937ff71443
IEDL.DBID AIKHN
ISSN 1368-8375
IngestDate Fri Aug 16 10:43:25 EDT 2024
Thu Sep 26 17:24:57 EDT 2024
Sat Sep 28 08:20:22 EDT 2024
Fri Feb 23 02:39:57 EST 2024
IsPeerReviewed true
IsScholarly true
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c380t-295fb1c078634594e7019a9c5a34a74fdd4cee1299b7f9b81c91dd937ff71443
Notes SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
PMID 36463699
PQID 2747002695
PQPubID 23479
PageCount 1
ParticipantIDs proquest_miscellaneous_2747002695
crossref_primary_10_1016_j_oraloncology_2022_106190
pubmed_primary_36463699
elsevier_sciencedirect_doi_10_1016_j_oraloncology_2022_106190
PublicationCentury 2000
PublicationDate January 2023
2023-01-00
20230101
PublicationDateYYYYMMDD 2023-01-01
PublicationDate_xml – month: 01
  year: 2023
  text: January 2023
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Oral oncology
PublicationTitleAlternate Oral Oncol
PublicationYear 2023
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Tardy, Di Mauro, Ebran, Refae, Bozec, Benezery (b0055) 2018; 80
Li, Luo, Huang, Luo, Zhu (b0015) 2020; 20
Griffith, Schmitt, Little, Magliocca (b0025) 2017; 141
Tonon, Modi, Wu, Kubo, Coxon, Komiya (b0030) 2003; 33
Cipriani, Lusardi, McElherne, Pearson, Olivas, Fitzpatrick (b0035) 2019; 43
Laurie, Ho, Fury, Sherman, Pfister (b0020) 2011; 12
Meyer, Broaddus, Lu (b0040) 2009; 16
Chan, Van Abel, Lewis, Routman, Garcia, Karp (b0010) 2021; 43
Peraza, Gómez, Beltran, Amarista (b0005) 2020; 121
Le, Kim, Van Cutsem, Geva, Jäger, Hara (b0045) 2020; 38
Marabelle, Le, Ascierto, Di Giacomo, De Jesus-Acosta, Delord (b0050) 2020; 38
Tonon (10.1016/j.oraloncology.2022.106190_b0030) 2003; 33
Tardy (10.1016/j.oraloncology.2022.106190_b0055) 2018; 80
Peraza (10.1016/j.oraloncology.2022.106190_b0005) 2020; 121
Le (10.1016/j.oraloncology.2022.106190_b0045) 2020; 38
Meyer (10.1016/j.oraloncology.2022.106190_b0040) 2009; 16
Li (10.1016/j.oraloncology.2022.106190_b0015) 2020; 20
Cipriani (10.1016/j.oraloncology.2022.106190_b0035) 2019; 43
Marabelle (10.1016/j.oraloncology.2022.106190_b0050) 2020; 38
Griffith (10.1016/j.oraloncology.2022.106190_b0025) 2017; 141
Chan (10.1016/j.oraloncology.2022.106190_b0010) 2021; 43
Laurie (10.1016/j.oraloncology.2022.106190_b0020) 2011; 12
References_xml – volume: 121
  start-page: 713
  year: 2020
  end-page: 720
  ident: b0005
  article-title: Mucoepidermoid carcinoma. An update and review of the literature
  publication-title: J Stomatol Oral Maxi
  contributor:
    fullname: Amarista
– volume: 43
  start-page: 885
  year: 2019
  end-page: 897
  ident: b0035
  article-title: Mucoepidermoid carcinoma
  publication-title: Am J Surg Pathol
  contributor:
    fullname: Fitzpatrick
– volume: 141
  start-page: 381
  year: 2017
  end-page: 395
  ident: b0025
  article-title: New developments in salivary gland pathology: Clinically useful ancillary testing and new potentially targetable molecular alterations
  publication-title: Arch Pathol Lab Med
  contributor:
    fullname: Magliocca
– volume: 43
  start-page: 2663
  year: 2021
  end-page: 2671
  ident: b0010
  article-title: Mucoepidermoid carcinoma of the parotid gland: twenty-year experience in treatment and outcomes
  publication-title: Head Neck
  contributor:
    fullname: Karp
– volume: 33
  start-page: 208
  year: 2003
  end-page: 213
  ident: b0030
  article-title: T(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway
  publication-title: Nat Genet
  contributor:
    fullname: Komiya
– volume: 16
  start-page: 14
  year: 2009
  end-page: 22
  ident: b0040
  article-title: Endometrial cancer and lynch syndrome: clinical and pathologic considerations
  publication-title: Cancer Control
  contributor:
    fullname: Lu
– volume: 80
  start-page: 104
  year: 2018
  end-page: 107
  ident: b0055
  article-title: Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma
  publication-title: Oral Oncol
  contributor:
    fullname: Benezery
– volume: 20
  start-page: 1
  year: 2020
  end-page: 13
  ident: b0015
  article-title: Microsatellite instability: a review of what the oncologist should know
  publication-title: Cancer Cell Int
  contributor:
    fullname: Zhu
– volume: 12
  start-page: 815
  year: 2011
  end-page: 824
  ident: b0020
  article-title: Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review
  publication-title: Lancet Oncol
  contributor:
    fullname: Pfister
– volume: 38
  start-page: 11
  year: 2020
  end-page: 19
  ident: b0045
  article-title: Phase II Open-Label study of pembrolizumab in Treatment-Refractory, microsatellite instability-High/Mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164
  publication-title: J Clin Oncol
  contributor:
    fullname: Hara
– volume: 38
  start-page: 1
  year: 2020
  end-page: 10
  ident: b0050
  article-title: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability/Mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study
  publication-title: J Clin Oncol
  contributor:
    fullname: Delord
– volume: 43
  start-page: 885
  issue: 7
  year: 2019
  ident: 10.1016/j.oraloncology.2022.106190_b0035
  article-title: Mucoepidermoid carcinoma
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000001252
  contributor:
    fullname: Cipriani
– volume: 141
  start-page: 381
  issue: 3
  year: 2017
  ident: 10.1016/j.oraloncology.2022.106190_b0025
  article-title: New developments in salivary gland pathology: Clinically useful ancillary testing and new potentially targetable molecular alterations
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/arpa.2016-0259-SA
  contributor:
    fullname: Griffith
– volume: 121
  start-page: 713
  issue: 6
  year: 2020
  ident: 10.1016/j.oraloncology.2022.106190_b0005
  article-title: Mucoepidermoid carcinoma. An update and review of the literature
  publication-title: J Stomatol Oral Maxi
  contributor:
    fullname: Peraza
– volume: 80
  start-page: 104
  year: 2018
  ident: 10.1016/j.oraloncology.2022.106190_b0055
  article-title: Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2018.04.001
  contributor:
    fullname: Tardy
– volume: 38
  start-page: 1
  issue: 1
  year: 2020
  ident: 10.1016/j.oraloncology.2022.106190_b0050
  article-title: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability/Mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.02105
  contributor:
    fullname: Marabelle
– volume: 33
  start-page: 208
  issue: 2
  year: 2003
  ident: 10.1016/j.oraloncology.2022.106190_b0030
  article-title: T(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway
  publication-title: Nat Genet
  doi: 10.1038/ng1083
  contributor:
    fullname: Tonon
– volume: 43
  start-page: 2663
  issue: 9
  year: 2021
  ident: 10.1016/j.oraloncology.2022.106190_b0010
  article-title: Mucoepidermoid carcinoma of the parotid gland: twenty-year experience in treatment and outcomes
  publication-title: Head Neck
  doi: 10.1002/hed.26735
  contributor:
    fullname: Chan
– volume: 12
  start-page: 815
  issue: 8
  year: 2011
  ident: 10.1016/j.oraloncology.2022.106190_b0020
  article-title: Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70245-X
  contributor:
    fullname: Laurie
– volume: 20
  start-page: 1
  issue: 1
  year: 2020
  ident: 10.1016/j.oraloncology.2022.106190_b0015
  article-title: Microsatellite instability: a review of what the oncologist should know
  publication-title: Cancer Cell Int
  contributor:
    fullname: Li
– volume: 16
  start-page: 14
  issue: 1
  year: 2009
  ident: 10.1016/j.oraloncology.2022.106190_b0040
  article-title: Endometrial cancer and lynch syndrome: clinical and pathologic considerations
  publication-title: Cancer Control
  doi: 10.1177/107327480901600103
  contributor:
    fullname: Meyer
– volume: 38
  start-page: 11
  issue: 1
  year: 2020
  ident: 10.1016/j.oraloncology.2022.106190_b0045
  article-title: Phase II Open-Label study of pembrolizumab in Treatment-Refractory, microsatellite instability-High/Mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.02107
  contributor:
    fullname: Le
SSID ssj0005150
Score 2.4176583
Snippet •We first to report a 64-year-old woman of Mucoepidermoid carcinoma of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases...
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 106190
SubjectTerms Abdominal Cavity - pathology
Carcinoma, Mucoepidermoid - pathology
Humans
Immune Checkpoint Inhibitors
Parotid Gland - pathology
Parotid Neoplasms - pathology
Title A remarkable clinical response to immune checkpoint inhibitors of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity
URI https://dx.doi.org/10.1016/j.oraloncology.2022.106190
https://www.ncbi.nlm.nih.gov/pubmed/36463699
https://search.proquest.com/docview/2747002695
Volume 136
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELbKVgIuqJTXAq2MxNXdPJzEPnBYlVZb0PbSIvUW2fGEhmrjVTZ76KX_iX_ITB48JCohodz8iK2M4_nGnpmPsfcQaesgswJ1kRIyLCOhXaCECVVqI3wU0I3u8jxdfJGfrpKrHXY8xsKQW-Ww9_d7erdbDyWz4WvO1lU1uwjjVKF5hQCiy5OOJtAuqiMpJ2x3fvZ5cf7L0yNM-mDhVAnqMOYe7dy8KA7e112G6Fs0F6PoiIwk2qL_rqfuw6GdPjrdY08GIMnn_Vyfsh2o99mjj-T8Q_xt--zhcrg2f8a-z3kDK9PcUJwUH4MhsazzjwXeel5RnAjWXUNxs_ZV3fKqvq5sRWQ83Jd8eXEmFpySG_OvjXHAl9vCA9HLNitfOV4QJ1HtV4YaI6jka9P4Fis6jhBOx718dF7kK2gNotINbHCUrrWxznf0YvgiYrN4zi5PTy6PF2LgahBFrIJWRDopbVgg4EhjmWgJlObd6CIxsTSZLJ2TqI4RXGibldqqsNChc4iNyjJDmcUv2KT2NbxiPIwKaZ0qiT1HQhCrFKICbBI4CEqZRVMWj4LJ131Gjnx0VfuW_y7OnMSZ9-Kcsg-jDPM_1leOquOf-r8bBZ_jD0i3KqYGv93kZNaTJauTKXvZr4if84pTysem9ev_HP0Ne0w09_3Rz1s2aZstHCAYau0he3B0Fx4OS_4HEPIN0g
link.rule.ids 315,786,790,4521,24144,27955,27956,45618,45712
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaqIlEuCMpreRqJa7qJ4yT2gUNVqLbQ9NJF6s2yY6cN1carbPbQS_8T_5AZJ0FFAgkJ5WY7iZVxZr6xZ-Yj5INj0lhXmAhskYh4UrNI2lhEOhG5YXAJhye65Vm--Ma_XGQXO-RoyoXBsMpR9w86PWjrsWU-fs35umnm50maC3CvAECEOungAt1DNIBxXQe3d-I8kmxIFc5FhMOnyqMhyAuz4H0b6kPfgLPI2AG6SKig_2yl_oZCgzU6fkQejjCSHg4zfUx2XLtP9j5h6A-yt-2T--V4aP6E_DiknVvp7hqzpOiUCgltITrW0d7TBrNEoO_KVddr37Q9bdqrxjRIxUN9Tcvzk2hBsbQxvey0dbTcVt4huWy38o2lFTIStX6lcTBASrrWne-hIzCEUNzspVPoIl25XgMm3bgNvCWM1sb6QC4GD0Iui6dkefx5ebSIRqaGqEpF3EdMZrVJKoAbecozyR0WedeyynTKdcFrazkYY4AW0hS1NCKpZGItIKO6LsCjS5-R3da37gWhCau4saJG7hzu4lTkjlXOZLF1cc0LNiPpJBi1HupxqClQ7bu6K06F4lSDOGfk4yRD9dvqUmA4_un-95PgFfx-eKaiW-e3G4VOPfqxMpuR58OK-DWvNMdqbFK-_M-3vyN7i2V5qk5Pzr6-Ig-Q8H7YBHpNdvtu694ALOrN27DsfwKC2w6n
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+remarkable+clinical+response+to+immune+checkpoint+inhibitors+of+MSI-H+high+grade+Mucoepidermoid+carcinoma+of+the+parotid+gland+with+multiple+metastases+in+the+abdominal+cavity&rft.jtitle=Oral+oncology&rft.au=Pan%2C+Yanling&rft.au=Li%2C+Yijie&rft.au=Yuan%2C+Feng&rft.au=Lin%2C+Zhiren&rft.date=2023-01-01&rft.eissn=1879-0593&rft.volume=136&rft.spage=106190&rft_id=info:doi/10.1016%2Fj.oraloncology.2022.106190&rft_id=info%3Apmid%2F36463699&rft.externalDocID=36463699
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1368-8375&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1368-8375&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1368-8375&client=summon